Zevra Therapeutics, Inc. revenue
Zevra Therapeutics, Inc.'s revenue was $106m in fiscal 2025, up 350.9% on the year before. Since fiscal 2019 ($12.8m) it has grown at a compound 42.3% a year. Over the last twelve months it was $136m.
Revenue history
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 13 | 13 | 29 | 10 | 27 | 24 | 106 | 136 |
| Growth on the year before | — | — | — | — | — | +3.5% | +115.6% | −64.5% | +170.3% | −14.0% | +350.9% | — |
| Gross profit | — | — | — | 0 | 3 | — | 27 | 10 | 25 | — | — | — |
| Gross margin | — | — | — | — | 22.1% | — | 92.8% | 97.8% | 89.3% | — | — | — |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| MIPLYFFA | $87.4M | ▲ 765.3% |
| Olpruva | $800,000 | ▲ 700.0% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Zevra Therapeutics, Inc.'s 10-K filed March 9, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Zevra Therapeutics, Inc. | $136m | 119.4% | 101.9% |
| Natural Alternatives International Inc | $143m | 9.7% | -2.6% |
| Niagen Bioscience, Inc. | $129m | 11.0% | 16.8% |
| Heron Therapeutics, Inc. | $151m | 1.0% | 8.6% |
| Eton Pharmaceuticals, Inc. | $106m | 81.5% | 53.8% |
| Amarin Corp plc\uk | $176m | -22.3% | -18.3% |
Compare with peers
- Natural Alternatives International Inc revenue
- Niagen Bioscience, Inc. revenue
- Heron Therapeutics, Inc. revenue
- Eton Pharmaceuticals, Inc. revenue
- Amarin Corp plc\uk revenue
Head to head: NAII vs ZVRANAGE vs ZVRAHRTX vs ZVRAETON vs ZVRA
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies